BC Week In Review | Dec 13, 2016
Clinical News

Tucatinib: Ph II HER2CLIMB amended

Cascadian (formerly Oncothyreon Inc.) amended the double-blind, placebo-controlled, international Phase II HER2CLIMB trial of oral tucatinib to increase enrollment to 480 patients from 180, allowing HER2CLIMB to serve as a single registration trial. HER2CLIMB is...
BC Week In Review | Jun 6, 2016
Clinical News

ONT-380: Additional Phase Ib data

Additional data from 32 evaluable patients with HER2-positive metastatic breast cancer who were heavily pretreated with Herceptin trastuzumab and a taxane in the open-label, dose-escalation, U.S. and Canadian Phase Ib Study ONT-380-004 showed that the...
BC Extra | Apr 27, 2016
Company News

Zymeworks, GSK in second antibody deal

Zymeworks Inc. (Vancouver, B.C.) granted GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) an option to license molecules developed using the biotech's Azymetric bispecific antibody discovery platform. The companies partnered in December to develop mAbs and bispecific antibodies with...
BC Extra | Mar 30, 2016
Company News

Management tracks

Gilead Sciences Inc. (NASDAQ:GILD) SVP of Hematology and Oncology Therapeutics Philippe Bishop has left the company. Oncology company Medivation Inc. (NASDAQ:MDVN) named Jennifer Jarrett CFO, effective April 23. She will replace Rick Bierly, who will...
BC Week In Review | Mar 7, 2016
Clinical News

ONT-380: Phase II started

Oncothyreon began a double-blind, placebo-controlled, international Phase II trial to evaluate 300 mg oral ONT-380 twice daily for 21 days plus Xeloda capecitabine and Herceptin trastuzumab in about 180 heavily pretreated patients with unresectable locally...
BC Extra | Jan 14, 2016
Company News

Management tracks

Rare disease company Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR) hired Mary Szela as CEO. Sandford Smith had been interim CEO since Marc Beer's resignation in July 2015. Szela was CEO of Melinta Therapeutics Inc. (New Haven, Conn.)....
BC Week In Review | Dec 14, 2015
Clinical News

ONT-380: Additional Phase Ib data

Data from 34 evaluable patients with HER2-positive metastatic breast cancer who were heavily pretreated with Herceptin trastuzumab and a taxane in an open-label, dose-escalation, U.S. and Canadian Phase Ib trial showed that twice-daily 300 mg...
BioCentury | Nov 23, 2015
Strategy

More with less

With 16 months under his belt as the new head of global R&D for Merck KGaA's biopharmaceuticals division, Luciano Rossetti has pruned the pipeline, accelerated the unit's cancer immunotherapy efforts and revived one late-stage program....
BC Innovations | Aug 6, 2015
Targets & Mechanisms

Caveat inhibitor

Two studies have shown that metabolic adaptations can allow some cancer cells to thrive in response to therapies that inhibit the PI3K pathway. The results could explain the poor clinical performance of the inhibitors, but...
BC Extra | Jul 14, 2015
Financial News

Financial tracks

Jay Venkatesan joined Alpine BioVentures as a managing partner. Venkatesan was EVP and general manager at Oncothyreon Inc. (NASDAQ:ONTY)....
Items per page:
1 - 10 of 422
BC Week In Review | Dec 13, 2016
Clinical News

Tucatinib: Ph II HER2CLIMB amended

Cascadian (formerly Oncothyreon Inc.) amended the double-blind, placebo-controlled, international Phase II HER2CLIMB trial of oral tucatinib to increase enrollment to 480 patients from 180, allowing HER2CLIMB to serve as a single registration trial. HER2CLIMB is...
BC Week In Review | Jun 6, 2016
Clinical News

ONT-380: Additional Phase Ib data

Additional data from 32 evaluable patients with HER2-positive metastatic breast cancer who were heavily pretreated with Herceptin trastuzumab and a taxane in the open-label, dose-escalation, U.S. and Canadian Phase Ib Study ONT-380-004 showed that the...
BC Extra | Apr 27, 2016
Company News

Zymeworks, GSK in second antibody deal

Zymeworks Inc. (Vancouver, B.C.) granted GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) an option to license molecules developed using the biotech's Azymetric bispecific antibody discovery platform. The companies partnered in December to develop mAbs and bispecific antibodies with...
BC Extra | Mar 30, 2016
Company News

Management tracks

Gilead Sciences Inc. (NASDAQ:GILD) SVP of Hematology and Oncology Therapeutics Philippe Bishop has left the company. Oncology company Medivation Inc. (NASDAQ:MDVN) named Jennifer Jarrett CFO, effective April 23. She will replace Rick Bierly, who will...
BC Week In Review | Mar 7, 2016
Clinical News

ONT-380: Phase II started

Oncothyreon began a double-blind, placebo-controlled, international Phase II trial to evaluate 300 mg oral ONT-380 twice daily for 21 days plus Xeloda capecitabine and Herceptin trastuzumab in about 180 heavily pretreated patients with unresectable locally...
BC Extra | Jan 14, 2016
Company News

Management tracks

Rare disease company Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR) hired Mary Szela as CEO. Sandford Smith had been interim CEO since Marc Beer's resignation in July 2015. Szela was CEO of Melinta Therapeutics Inc. (New Haven, Conn.)....
BC Week In Review | Dec 14, 2015
Clinical News

ONT-380: Additional Phase Ib data

Data from 34 evaluable patients with HER2-positive metastatic breast cancer who were heavily pretreated with Herceptin trastuzumab and a taxane in an open-label, dose-escalation, U.S. and Canadian Phase Ib trial showed that twice-daily 300 mg...
BioCentury | Nov 23, 2015
Strategy

More with less

With 16 months under his belt as the new head of global R&D for Merck KGaA's biopharmaceuticals division, Luciano Rossetti has pruned the pipeline, accelerated the unit's cancer immunotherapy efforts and revived one late-stage program....
BC Innovations | Aug 6, 2015
Targets & Mechanisms

Caveat inhibitor

Two studies have shown that metabolic adaptations can allow some cancer cells to thrive in response to therapies that inhibit the PI3K pathway. The results could explain the poor clinical performance of the inhibitors, but...
BC Extra | Jul 14, 2015
Financial News

Financial tracks

Jay Venkatesan joined Alpine BioVentures as a managing partner. Venkatesan was EVP and general manager at Oncothyreon Inc. (NASDAQ:ONTY)....
Items per page:
1 - 10 of 422